You just read:

Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year

News provided by

Sosei Group Corporation

Aug 30, 2012, 02:11 ET